Optimization of Extraction Methods for Determination of Phosphodiesterase-5 (PDE5) Inhibitors in Premix Coffee

被引:0
|
作者
Zailina, A. M. [1 ]
Aminah, A. [2 ]
Ambar, Y. Mohd. [2 ]
机构
[1] Minist Hlth, Natl Publ Hlth Lab, Sg Buloh 47000, Selangor, Malaysia
[2] Univ Kebangsaan Malaysia, Sch Chem Sci & Food Technol, Fac Sci & Technol, Bangi 43600, Selangor, Malaysia
来源
SAINS MALAYSIANA | 2013年 / 42卷 / 02期
关键词
HPLC-DAD; LC-MS-TOF; optimization; PDE5; inhibitors; premix coffee; PERFORMANCE LIQUID-CHROMATOGRAPHY; DIETARY-SUPPLEMENTS; STRUCTURE ELUCIDATION; MASS-SPECTROMETRY; SMALL VOLUMES; SILDENAFIL; VARDENAFIL; TADALAFIL; ADULTERANTS; MEDICINES;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
An efficient analytical technique capable of analyzing three most common phosphodiesterase-5 (PDE5) inhibitors (vardenafil, sildenafil and tadalafil) simultaneously in premix coffee was developed. Sample extractions using either acetonitrile or methanol with two different extraction techniques (with and without evaporation steps) were evaluated. Identification and quantitation was conducted by high performance liquid chromatography with photo-diode-array (HPLC-DAD) at different wavelengths; 230 nm, 245 nm and 290 nm; and by time of flight mass spectrometry (LC-MS-TOF). Extraction with acetonitrile (without evaporation with nitrogen) showed recovery ranging from 105% to 113% (+/-< 10%) for HPLC-DAD at 245 nm and 93% to 102% (+/-< 2.5%) for LC-MS-TOF. Chromatogram separation was best achieved with mobile phase consisted of water (0.1% formic acid) and acetonitrile (0.1% formic acid) with gradient elution within 20 min. Thus, the results indicated that extraction using acetonitrile without evaporation step was the most efficient technique for determination of PDE5 inhibitors in premix coffee.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 50 条
  • [1] Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors
    Blount, Mitsi A.
    Zoraghi, Roya
    Bessay, Emmanuel P.
    Beasley, Alfreda
    Francis, Sharron H.
    Corbin, Jackie D.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02): : 730 - 737
  • [2] Comparison of phosphodiesterase type 5 (PDE5) inhibitors
    Wright, P. J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) : 967 - 975
  • [3] Evidence for Pleiotropic Effects of Phosphodiesterase-5 (PDE5) Inhibitors: Emerging Concepts in Cancer and Cardiovascular Medicine
    Gross, Garrett J.
    [J]. CIRCULATION RESEARCH, 2011, 108 (09) : 1040 - 1041
  • [4] Regional effects of phosphodiesterase-5 (pde5) inhibitors on gastric smooth muscle contractility in vitro.
    Martin, JS
    Thomas, RM
    Ryan, JP
    Parkman, HP
    [J]. GASTROENTEROLOGY, 2005, 128 (04) : A548 - A548
  • [5] Role of phosphodiesterase-5 (PDE5) in altered vascular reactivity in cirrhotic rats
    Sabra, R
    Tahseldar-Roumieh, R
    Ghali, R
    Tumeh, Y
    El-Hajj, I
    Lugnier, C
    [J]. FASEB JOURNAL, 2004, 18 (05): : A983 - A983
  • [6] Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach
    Ongaro, Alberto
    Zagotto, Giuseppe
    Memo, Maurizio
    Gianoncelli, Alessandra
    Ribaudo, Giovanni
    [J]. NATURAL PRODUCT RESEARCH, 2021, 35 (10) : 1648 - 1653
  • [7] Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review
    Manna, Sayan
    Gray, Mingyang Liu
    Kaul, Vivian F.
    Wanna, George
    [J]. OTOLOGY & NEUROTOLOGY, 2019, 40 (03) : 276 - 283
  • [8] Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
    Dorsey, Philip
    Keel, Christopher
    Klavens, Meghan
    Hellstrom, Wayne J. G.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1109 - 1122
  • [9] Phosphodiesterase-5 (PDE-5) Inhibitors as Emergent Environmental Contaminants: Advanced Remediation and Analytical Methods
    Bianco, Giuliana
    Foti, Luca
    Pascale, Raffaella
    Lelario, Filomena
    Coviello, Donatella
    Brienza, Monica
    Bufo, Sabino Aurelio
    Scrano, Laura
    [J]. WATER, 2021, 13 (20)
  • [10] AOAC SMPR 2014.011: Determination of phosphodiesterase type 5 (PDE5) inhibitors in dietary ingredients and supplements
    Mastovska, Katerina
    Arora, Saurabh
    Betz, Joseph
    Bzhelyansky, Anton
    Cain, Teresa
    Chlenov, Anatoly
    Edwards, John
    Giancaspro, Gabriel
    Hildreth, Jana
    Ingle, Prashant
    Kennedy, David
    Koch, Todd
    Krynitsky, Alexander
    Lock, Stephen
    Neal-Kababick, James
    Nickum, Elisa
    Phillips, Melissa
    Rimmer, Catherine
    Royce, Steve
    Schaneberg, Brian
    Shimelis, Olga
    Sullivan, Darryl
    Travis, John
    Vaclavik, Lukas
    Yu, Kate
    Zielinski, Garrett
    Zweigenbaum, Jerry
    Coates, Scott
    [J]. Journal of AOAC International, 2015, 98 (04) : 1064 - 1067